A large retrospective study suggests that a magnetic resonance imaging (MRI) marker — called “brain atrophied T2 lesion volume” —…
Patricia Inacio, PhD
Patricia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. She also served as a PhD student research assistant in the Department of Microbiology & Immunology, Columbia University, New York, for which she was awarded a Luso-American Development Foundation (FLAD) fellowship.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Patricia Inacio, PhD
Two potassium ion channels located at gaps between segments of myelin are required for high frequency and high-speed conduction of electrical impulses along myelin-rich nerves, a study shows. Loss of the workings of these potassium channels in what are called the nodes of Ranvier slowed nerve conduction, and impaired the sensory response of a rat. These findings suggest that similar problems with these channels may exist in people with multiple sclerosis (MS). The study “TREK-1 and TRAAK Are Principal K+ Channels at the Nodes of Ranvier for Rapid Action Potential Conduction on Mammalian Myelinated Afferent Nerves” was published in the journal Neuron. Myelin, the fat-rich substance that wraps around nerve fibers (axons), works to insulate and increase the velocity of the signals relayed by nerve cells. Gaps between segments of myelin, or nodes of Ranvier, also work to amplify these signals. Nerve impulses must travel and arrive at relay points extremely quickly for effective connection and communication between brain regions. Researchers at the University of Alabama at Birmingham (UAB) showed for the first time that the nodes of Ranvier have potassium channels that allow the myelinated nerves to propagate nerve impulses at very high frequencies, and with high conduction speeds. This is key for fast transmission of sensations and rapid muscle control in mammals. The nodes of Ranvier were first discovered in 1878 by the French scientist Louis-Antoine Ranvier. Later research, dating from 1939, showed that they work as relay stations placed along myelinated nerves — about 1 millimeter apart — for proper conduction of nerve impulses at rates of 50 to 200 meters per second. Between these nodes, the nerve is wrapped in myelin. When the nerve fires, the electrical impulse travels along the nerve (called action potential) from one node to the other at a speed 100 times faster than that of impulses in nerves lacking myelin. Neuroscientists know that ions crossing the membrane of nerve cells are required to fire electrical impulses along nerves, but whether potassium ion channels were present in the nodes of Ranvier remained a matter of debate. No one had been able to use patch clamps — a technique that allows recording of whole-cell or single-ion channel currents flowing across membranes — to the nodes of the small intact nerves in mammals. UAB researchers led by Jianguo Gu, PhD, worked with a rat and identified two ion channels, called TREK-1 and TRAAK, as the main potassium channels in the nodes of Ranvier of the rat’s myelinated nerve. Most importantly, they showed these ion channels allow high-speed and high frequency conduction of nerve impulses along the myelinated afferent nerves — those carrying information from the sensory organs (like the eyes or skin) to the central nervous system (the brain and spinal cord). TREK-1 and TRAAK channels were highly enriched — 3,000 times higher — at the nodes of Ranvier in afferent nerves than in the nerve cell’s body. When the scientists removed (knocked down) these channels, conduction speed in the rat's nerve dropped by 50 percent, and the rat's "aversion reaction" to its whisker being flicked was slower. "TREK-1 and TRAAK are clustered at nodes of Ranvier of myelinated afferent nerves," the researchers concluded, and "suppressing these channels retards nerve conduction and impairs sensory functions." Increasing evidence shows that dysfunction in the nodes of Ranvier are present in neurological diseases, including MS. Whether autoantibodies (antibodies that attack the body’s own tissues) target the TREK-1 and TRAAK to affect nerve conduction, leading to sensory and motor problems such as those seen in MS, remains to be investigated, Gu said in a UAB news release written by Jeff Hansen.
Pharmascience recently launched pms-Fingolimod, a generic version of Novartis’ Gilenya (fingolimod), to treat adults with relapsing-remitting multiple sclerosis (RRMS) in Canada.
The U.S. Food and Drug Administration (FDA) has approved Vumerity (diroximel fumarate) for the treatment of relapsing forms of multiple…
The National Multiple Sclerosis Society (NMSS) awarded $14.6 million in grants supporting 43 new and multiyear research projects into multiple sclerosis (MS), part of…
Newer disease-modifying treatments for multiple sclerosis (MS) are effective but also known to carry a greater risk of infections in…
Targeting the chemokine receptor CXCR6, a protein at the surface of a certain group of T helper cells, prevented the development…
Profiling Inflammatory Markers in Cerebrospinal Fluid of Importance in Active MS, Case Study Finds
Careful profiling of inflammatory markers in cerebrospinal fluid (CSF) of multiple sclerosis patients, coupled with standard exams and scans, helps…
#ECTRIMS2019 – Data Shows Ublituximab’s Long-term Safety in Relapsing MS, TG Therapeutics Announced
Ublituximab continues to be safe and well-tolerated by people with relapsing forms of multiple…
Late-line use of H.P. Acthar Gel to treat relapses in adults with multiple sclerosis (MS) is linked with lower costs than…
Relapses in people with multiple sclerosis (MS) are associated with greater medical and non-medical costs, according to real-world data from…
Damage to nerve cells appears to occur years before people with multiple sclerosis (MS) begin to show symptoms and is…
Oxcarbazepine, an anti-epileptic medicine, given in combination with a disease-modifying therapy (DMT) may help to stop disability progression in multiple…
People with multiple sclerosis (MS) are more likely to develop cardiovascular diseases than the general population, according to a…
Treatment for more than six years with Ocrevus (ocrelizumab) is linked to lower levels of blood antibodies among people with …
New 10-year data from the Phase 3 ENDORSE trial confirms the long-term benefits of Biogen’s Tecfidera for patients with…
Serum neurofilament light chain (sNfL) in the blood — a proposed biomarker for multiple sclerosis (MS) — is linked…
The out-of-pocket costs for self-administered disease-modifying therapies (DMTs) for multiple sclerosis (MS) patients on Medicare increased more than sevenfold…
The relationship between fatigue and patterns of physical activity in people with multiple sclerosis (MS) is not straightforward.
Our brains — much like our joints — stiffen with age, causing brain stem cells called oligodendrocyte progenitor cells (OPCs)…
Relapsing-remitting multiple sclerosis (RRMS) patients treated with Lemtrada (alemtuzumab) may develop additional (secondary) autoimmune reactions. Anti-CD20 therapies, including rituximab or…
Early and continuous treatment with Gilenya (fingolimod) in young people — those ages 30 years or younger — with…
Gilenya (fingolimod) has been approved in China as a disease-modifying therapy to treat adults and children, ages 10 and…
The Phase 2 clinical trial testing BrainStorm Cell Therapeutic’s investigational NurOwn therapy for progressive multiple sclerosis (MS) has added…
Targeting a protein found in immune T-cells called Oct1 may help prevent the misguided immune response seen in autoimmune diseases…
A new radiotracer called [F-18]PBR06, used in positron emission tomography (PET) imaging, helps detect changes in the brain’s grey…
Merck KGaA presented new evidence supporting the safety and clinical efficacy of Rebif (interferon beta-1a) for relapsing-remitting multiple…
Arbaclofen extended-release (ER) tablets taken twice a day can effectively reduce spasticity (muscle stiffness) in patients with multiple sclerosis (MS) with…
Treatment with Sanofi Genzyme’s Lemtrada (alemtuzumab) for up to two years lowers the levels of serum neurofilament light chain (sNfL),…
Human Blood-brain Barrier in a Chip, Created in the Lab, May Help Design New Therapies, Study Shows
By tweaking stem cells in a laboratory, researchers were able to generate a model of the human blood-brain barrier…